Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Gyre Therapeutics (GYRE) over the last 15 years, with Q3 2025 value amounting to $58000.0.

  • Gyre Therapeutics' Current Deferred Revenue rose 6111.11% to $58000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $58000.0, marking a year-over-year increase of 6111.11%. This contributed to the annual value of $61000.0 for FY2024, which is 5641.03% up from last year.
  • Per Gyre Therapeutics' latest filing, its Current Deferred Revenue stood at $58000.0 for Q3 2025, which was up 6111.11% from $28000.0 recorded in Q1 2025.
  • Gyre Therapeutics' 5-year Current Deferred Revenue high stood at $2.0 million for Q2 2021, and its period low was $28000.0 during Q1 2025.
  • In the last 5 years, Gyre Therapeutics' Current Deferred Revenue had a median value of $59500.0 in 2024 and averaged $409333.3.
  • Data for Gyre Therapeutics' Current Deferred Revenue shows a peak YoY increase of 51757.58% (in 2021) and a maximum YoY decrease of 8840.14% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Current Deferred Revenue stood at $230000.0 in 2021, then tumbled by 36.96% to $145000.0 in 2022, then crashed by 73.1% to $39000.0 in 2023, then soared by 56.41% to $61000.0 in 2024, then fell by 4.92% to $58000.0 in 2025.
  • Its Current Deferred Revenue was $58000.0 in Q3 2025, compared to $28000.0 in Q1 2025 and $61000.0 in Q4 2024.